Antibodies News and Research

RSS

Scientists develop playbook to end devastating impact of fibrotic diseases

A team of scientists has developed a playbook for ending the devastating impact of fibrotic diseases of the liver, lung, kidney, and other organs, which are responsible for as many as 45 percent of all deaths in the industrialized world.

11 Jan 2013

TSRI chemists develop new cell-marking method

Chemists at The Scripps Research Institute (TSRI) have found an easier way to perform one of the most fundamental tasks in molecular biology. Their new method allows scientists to add a marker to certain cells, so that these cells may be easily located and/or selected out from a larger cell population.

10 Jan 2013

Prion filtration tested for red blood cell transfusions

Red blood cell prion filtration does not increase the risk for alloimmunization or transfusion reactions, suggest results from the largest safety study to date.

9 Jan 2013

Adolescents may lose hepatitis B virus protection despite vaccination as infants

New research reveals that a significant number of adolescents lose their protection from hepatitis B virus (HBV) infection, despite having received a complete vaccination series as infants. Results in the January 2013 issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, suggest teens with high-risk mothers (those positive for HBeAg) and teens whose immune system fails to remember a previous viral exposure (immunological memory) are behind HBV reinfection.

8 Jan 2013

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award.

8 Jan 2013

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody program to enter the clinic in just three years from initiation of discovery.

7 Jan 2013

High vitamin D in pregnancy may increase food allergy risk in children

Study results published in Allergy suggest that supplementing pregnant women with vitamin D may increase their children’s risk for developing food allergy in infancy.

4 Jan 2013

EPIRUS’ BOW-015 achieves bioequivalence to Remicade in a single dose comparator trial

EPIRUS Biopharmaceuticals, Inc., formerly known as fourteen22 Inc, announced that its lead asset, BOW-015, achieved bioequivalence to Remicade in a single dose comparator trial.

3 Jan 2013

T. gondii infection linked to bipolar disorder risk

Results from a French study support an association between Toxoplasma gondii infection and bipolar disorder.

2 Jan 2013

Small numbers of ANA- and RP-negative patients with systemic sclerosis

There exists a very small subgroup of patients with systemic sclerosis who lack circulating antinuclear antibodies and who do not have Raynaud's phenomenon, research shows.

31 Dec 2012

Immune response more complicated than thought

Researchers have found that the orientation and concentration of antibodies could determine the control of bacterial infection.

28 Dec 2012

Antibody type prognostic for myasthenia gravis patients

Patients who have myasthenia gravis are more likely to have a severe form of the disease and more difficulty achieving remission if they are seropositive for antibodies to muscle-specific kinase, report researchers.

24 Dec 2012

Towards imaging biological processes in action at the atomic level

If the key to winning battles is knowing both your enemy and yourself, then scientists are now well on their way toward becoming the Sun Tzus of medicine by taking a giant step toward a priceless advantage - the ability to see the soldiers in action on the battlefield.

21 Dec 2012

Molecule imitating a virus may trigger inappropriate immune response

Why would our immune system turn against our own cells? This is the question that the combined Inserm/CNRS/ Pierre and Marie Curie University/Association Institut de Myologie have strived to answer in their "Therapies for diseases of striated muscle", concentrating in particular on the auto-immune disease known as myasthenia gravis.

21 Dec 2012

House passes bio-threat vaccines, Medicare coverage bills

The House passed several health measures Wednesday including bills on developing vaccines to thwart bio-threats and on Medicare coverage for immune deficiency care.

21 Dec 2012

New technique to directly image biological structures at atomic levels

Investigators at the Virginia Tech Carilion Research Institute have invented a way to directly image biological structures at their most fundamental level and in their natural habitats. The technique is a major advancement toward the ultimate goal of imaging biological processes in action at the atomic level.

21 Dec 2012

V-chip could allow health care providers to do 50 different tests in one go

A new device about the size of a business card could allow health care providers to test for insulin and other blood proteins, cholesterol, and even signs of viral or bacterial infection all at the same time—with one drop of blood. Preliminary tests of the V-chip, created by scientists at The Methodist Hospital Research Institute and MD Anderson Cancer Center, were published last night by Nature Communications.

20 Dec 2012

Zoo data show low incidence of animal–human infection

Zoonotic transmission rates are low and the risk for animal–human infection is well managed, show zoo data spanning 19 years.

19 Dec 2012

Allakos closes $32M Series A financing to develop antibody-based therapeutics

Allakos Inc. announced today that it has completed a $32 million Series A preferred stock financing led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund. Peter Moldt , PhD., Partner at Novo Ventures, Robert Alexander , PhD., Director at Alta Partners and John McKearn PhD., Managing Director at RiverVest Venture Partners, will join the Board of Directors.

17 Dec 2012

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

14 Dec 2012